These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32354928)

  • 1. Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors.
    Hada T; Miyamoto M; Ishibashi H; Kawauchi H; Soyama H; Matsuura H; Sakamoto T; Kakimoto S; Aoyama T; Iwahashi H; Suzuki R; Tsuda H; Takano M
    In Vivo; 2020; 34(3):1341-1346. PubMed ID: 32354928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytological Appearances of Ovarian Seromucinous Borderline Tumor in Ascites: Presentation of 2 Cases.
    Kai K; Hashiguchi M; Kurihara M; Tanaka Y; Kitamura S; Nakamura M; Shichijo C; Yamamoto-Rikitake M; Okuma R; Hikari T; Okuma E; Uchiyama M; Aoki S; Nakao Y; Yokoyama M; Aishima S
    Acta Cytol; 2021; 65(5):440-447. PubMed ID: 34284376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
    Wu RC; Chen SJ; Chen HC; Tan KT; Jung SM; Lin CY; Chao AS; Huang KG; Chou HH; Chang TC; Chao A; Lai CH
    Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis.
    Yun BS; Won S; Kim JH; Lee N; Kim M; Kim MK; Kim ML; Jung YW; Kim JY; Seong SJ; Shin E
    J Ovarian Res; 2022 Apr; 15(1):41. PubMed ID: 35387670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of Seromucinous Borderline Tumor from Serous Borderline Tumor on MR Imaging.
    Kurata Y; Kido A; Moribata Y; Kameyama K; Minamiguchi S; Konishi I; Togashi K
    Magn Reson Med Sci; 2018 Jul; 17(3):211-217. PubMed ID: 28993546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of MR imaging findings and quantitative values in the differentiation of seromucinous borderline tumour from endometriosis-related malignant ovarian tumour.
    Kurata Y; Kido A; Moribata Y; Kameyama K; Himoto Y; Minamiguchi S; Konishi I; Togashi K
    Eur Radiol; 2017 Apr; 27(4):1695-1703. PubMed ID: 27553934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seromucinous ovarian tumor A comparison with the rest of ovarian epithelial tumors.
    Karpathiou G; Chauleur C; Corsini T; Venet M; Habougit C; Honeyman F; Forest F; Peoc'h M
    Ann Diagn Pathol; 2017 Apr; 27():28-33. PubMed ID: 28325358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
    Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
    Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic Features and the Loss of ARID1A Expression in Ovarian Seromucinous Borderline Tumors and Seromucinous Carcinomas.
    Ok Atılgan A; Özen Ö; Haberal Reyhan AN; Ayhan A
    Int J Surg Pathol; 2023 Jun; 31(4):398-408. PubMed ID: 36452965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of ARID1A in ovarian seromucinous neoplasms and its clinicopathological significance].
    Ding XH; Tian X; Wang LQ; Wang Y; Liu AJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Jun; 49(6):588-593. PubMed ID: 32486536
    [No Abstract]   [Full Text] [Related]  

  • 12. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian seromucinous tumors: clinicopathological features of 10 cases with a detailed review of the literature.
    Idrees R; Din NU; Siddique S; Fatima S; Abdul-Ghafar J; Ahmad Z
    J Ovarian Res; 2021 Mar; 14(1):47. PubMed ID: 33736662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic carcinoma in ovarian seromucinous cystic tumor of borderline malignancy.
    Okumura T; Muronosono E; Tsubuku M; Terao Y; Takeda S; Maruyama M
    J Ovarian Res; 2018 Sep; 11(1):77. PubMed ID: 30176911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive.
    Vang R; Gown AM; Barry TS; Wheeler DT; Ronnett BM
    Int J Gynecol Pathol; 2006 Jan; 25(1):83-9. PubMed ID: 16306790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian Clear Cell Tumors Associated With Seromucinous Borderline Tumor: A Case Series.
    Vroobel KM; McCluggage WG
    Int J Gynecol Pathol; 2022 Jan; 41(1):76-81. PubMed ID: 33741765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases.
    Bostwick DG; Tazelaar HD; Ballon SC; Hendrickson MR; Kempson RL
    Cancer; 1986 Nov; 58(9):2052-65. PubMed ID: 3756820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A diagnostic challenge of seromucinous borderline tumor: A case report.
    Liu T; Sumida D; Wada T; Maehana T; Yamawaki A; Sugimoto S; Kawahara N; Yoshimoto C; Kobayashi H
    Medicine (Baltimore); 2019 May; 98(22):e15707. PubMed ID: 31145284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three cases of seromucinous carcinoma of the ovary arising in endometriotic cysts.
    Taga Y; Chigusa Y; Minamiguchi S; Kido A; Horikawa N; Horie A; Hamanishi J; Kondoh E; Mandai M; Yamaguchi K
    Int Cancer Conf J; 2021 Jan; 10(1):46-53. PubMed ID: 33489701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.